Buy or sell Rakuten Aspyrian stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Rakuten Aspyrian Stock
Tumor-targeted precision therapies
About Rakuten Aspyrian Stock
Rakuten Aspyrian is a privately funded clinical stage biotechnology company developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy. Photoimmunotherapy combines key advantages of antibody-mediated targeting of the cancer cells to achieve high tumor specificity, together with laser-activation of a biophysical mechanism that induces rapid cancer cell death with precision. Treatments with the Photoimmunotherapy platform lead to targeted and rapid tumor cell death by necrosis, with minimal effects on normal tissue. Rakuten Aspyrian is studying Photoimmunotherapy for use as a monotherapy and in combination with other drugs. Founded in 2013, the company is based in San Diego, California.
Investors
SBI Group
Funding History
| January 2015 | $8.4M |
|---|---|
| July 2015 | $4.3M |
| March 2016 | $40.0M |
| July 2017 | $15.1M |
| August 2018 | $150M |
| December 2018 | $134M |
Management
Chief Executive Officer
Hiroshi Mikitani
COO & President
Takashi Toraishi
Chief Technical Officer
Carlos A. Garcia
Finances and Operations
Agatha Martindale
Head of Chemistry
Lew Makings
Press
strictlyvc - Mar, 11 2016
xconomy - Mar, 11 2016
finsmes - Jul, 28 2015
businesswire - Apr, 30 2015
businesswire - Apr, 30 2015
xconomy - Apr, 23 2015
fiercebiotech - Jan, 27 2015
socaltech - Jan, 27 2015
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
